arrow
P

Pier Luigi Zinzani

Istituto di Ematologia di Bologna
H指数:117
被引数:6.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Management of advanced mycosis fungoides and Sézary Syndrome: International Recommendations for systemic treatments and allogeneic hematopoietic cell transplantation from the European Hematology Association, the EORTC Cutaneous Lymphoma Tumours Group, the International Society for Cutaneous Lymphoma, and the Lymphoma Working Party of the EBMT

欧洲血液学协会、欧洲组织肿瘤研究治疗协作组皮肤淋巴瘤肿瘤组、国际皮肤淋巴瘤学会和EBMT淋巴瘤工作组关于高级别真菌病样肉芽肿和Sézary综合征的管理:系统性治疗和异基因造血细胞移植的国际建议

2026-11-050
OAAI
Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

BRUIN 1/2 期研究的最终分析:评估吡鲁托布替尼单药治疗 <scp>MCL</scp> 患者的安全性和有效性

2026-11-040
OAAI
BEAM versus EAM, FEAM, BeEAM, and TEAM: exploring conditioning strategies in autologous stem cell transplantation for Hodgkin lymphoma a retrospective study of the LWP of EBMT

BEAM与EAM、FEAM、BeEAM和TEAM的比较:探索霍奇金淋巴瘤自体干细胞移植中的调理策略——EBMT LWP的一项回顾性研究

2026-10-060
PRE
Correction to: Modern and multidisciplinary care in polycythemia vera

对:多学科护理在真性红细胞增多症中的应用

2026-07-250
OAAI
Short BRAF+MEK coinhibition, alone and combined with anti-CD20 immunotherapy, in relapsed or refractory hairy cell leukemia: An investigator-sponsored multi-center phase 2 clinical trial

短期BRAF+MEK协同抑制,单独或联合抗CD20免疫疗法,在复发或难治性毛细胞白血病中的应用:一项研究者发起的多中心II期临床试验

2026-07-090
OAAI
Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

固定疗程的pirtobrutinib联合venetoclax–rituximab与venetoclax–rituximab治疗既往接受过治疗的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者(BRUIN CLL-322):一项开放标签、多中心、随机对照、III期临床试验

2026-07-090
OAAI
First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations

一线伊布替尼联合维奈克拉治疗≥65岁或TP53突变的外套细胞淋巴瘤(非母细胞样型)

Blood
IF23.1
2026-07-030
OA
LY08 Real-world outcomes and survival with targeted and established systemic therapies in advanced-stage cutaneous T-cell lymphoma: an updated PROCLIPI analysis

LY08 晚期皮肤T细胞淋巴瘤靶向治疗与标准系统性治疗的实际疗效及生存结局:PROCLIPI研究的更新分析

2026-06-260
OAAI
Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study

occult 乙型肝炎病毒感染状态与抗CD19 CAR-T细胞疗法治疗淋巴瘤的疗效受损无关,并显示出独特的免疫毒性特征:CART-SIE研究的结果

2026-05-210
OAAI
Frontline nilotinib vs dasatinib in NEwly diagnosed chronic phase chronic myeloid leukemia: a propensity score analysis based on AIFA monitoring registries

一线尼洛替尼与达沙替尼在 newly diagnosed 慢性期慢性髓性白血病中的比较:基于 AIFA 监测登记研究的倾向性评分分析

2026-04-240
PRE
Modern and multidisciplinary care in polycythemia vera

现代多学科护理在真性红细胞增多症中的应用

2026-04-180
OAAI
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

奥加曲沙在瓦尔登斯特伦巨球蛋白血症中,5年随访显示持久应答

2026-04-170
OAAI
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma

真实世界多中心研究:检查点抑制剂在复发/难治性原发纵隔B细胞淋巴瘤中的应用

2026-04-100
PRE
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

更正: Brentuximab vedotin联合化疗治疗一线系统性间变性大细胞淋巴瘤: 5年随访时ECHELON-2研究的亚组分析

2026-01-280
OAAI
Health-Related Quality of Life and Symptom Burden in Patients with Diffuse Large B-Cell Lymphoma Before Treatment with Tafasitamab and Lenalidomide: An Ad Hoc Analysis of Italian Real-World Data from the PRO-MIND Study

与健康相关的生活质量及症状负担:在接受Tafasitamab和Lenalidomide治疗前的弥漫性大B细胞淋巴瘤患者:PRO-MIND研究意大利真实世界数据的临时分析

2025-12-150
OAAI